Published September 1, 2016 | Version v1
Journal article

Reduction of hexavalent chromium by fasted and fed human gastric fluid. II. Ex vivo gastric reduction modeling

  • 1. Summit Toxicology, Orange Village, OH, 44022 (United States)
  • 2. ToxStrategies, Inc., Mission Viejo, CA, 92692 (United States)
  • 3. Summit Toxicology, Allenspark, CO, 8040 (United States)
  • 4. Brooks Applied Labs, Bothell, WA, 98011 (United States)
  • 5. Department of Health Sciences, University of Genoa, 16132 Genoa (Italy)
  • 6. Duke University Medical Center, Department of Surgery, Durham, NC, 27710 (United States)
  • 7. ToxStrategies, Inc., Katy, TX, 77494 (United States)
  • 8. ToxStrategies, Inc., Austin, TX, 78751 (United States)

Description

To extend previous models of hexavalent chromium [Cr(VI)] reduction by gastric fluid (GF), ex vivo experiments were conducted to address data gaps and limitations identified with respect to (1) GF dilution in the model; (2) reduction of Cr(VI) in fed human GF samples; (3) the number of Cr(VI) reduction pools present in human GF under fed, fasted, and proton pump inhibitor (PPI)-use conditions; and (4) an appropriate form for the pH-dependence of Cr(VI) reduction rate constants. Rates and capacities of Cr(VI) reduction were characterized in gastric contents from fed and fasted volunteers, and from fasted pre-operative patients treated with PPIs. Reduction capacities were first estimated over a 4-h reduction period. Once reduction capacity was established, a dual-spike approach was used in speciated isotope dilution mass spectrometry analyses to characterize the concentration-dependence of the 2nd order reduction rate constants. These data, when combined with previously collected data, were well described by a three-pool model (pool 1 = fast reaction with low capacity; pool 2 = slow reaction with higher capacity; pool 3 = very slow reaction with higher capacity) using pH-dependent rate constants characterized by a piecewise, log-linear relationship. These data indicate that human gastric samples, like those collected from rats and mice, contain multiple pools of reducing agents, and low concentrations of Cr(VI) (< 0.7 mg/L) are reduced more rapidly than high concentrations. The data and revised modeling results herein provide improved characterization of Cr(VI) gastric reduction kinetics, critical for Cr(VI) pharmacokinetic modeling and human health risk assessment. - Highlights: • SIDMS allows for measurement of Cr(VI) reduction rate in gastric fluid ex vivo • Human gastric fluid has three reducing pools • Cr(VI) in drinking water at < 0.7 mg/L is rapidly reduced in human gastric fluid • Reduction rate is concentration- and pH-dependent • A refined PK model is used to characterize inter-individual variability in Cr(VI) gastric reduction capacity

Availability note (English)

Available from http://dx.doi.org/10.1016/j.taap.2016.07.002

Additional details

Identifiers

DOI
10.1016/j.taap.2016.07.002;
PII
S0041-008X(16)30176-4;

Publishing Information

Journal Title
Toxicology and Applied Pharmacology
Journal Volume
306
Journal Page Range
p. 120-133
ISSN
0041-008X
CODEN
TXAPA9

Optional Information

Copyright
Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.